Home > Boards > US Listed > Biotechs > United Therapeutics Corporation (UTHR)

New drug application for high blood pressure rejected

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
mlkrborn Member Profile
 
Followed By 39
Posts 7,816
Boards Moderated 1
Alias Born 01/04/06
160x600 placeholder
United Therapeutics Pursues New Claims For Trade Secret Misappropriation Against Liquidia PR Newswire (US) - 6/7/2021 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/3/2021 6:03:55 AM
United Therapeutics Announces First Patient Enrolled In Phase 3 TETON Study Of Tyvaso In Patients With Idiopathic Pulmonary F... PR Newswire (US) - 6/3/2021 6:00:00 AM
Specialized Disclosure Report (sd) Edgar (US Regulatory) - 6/1/2021 4:31:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2021 4:42:57 PM
United Therapeutics Corporation To Present At The Jefferies Virtual Healthcare Conference PR Newswire (US) - 5/25/2021 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/12/2021 4:35:26 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2021 4:33:42 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/10/2021 4:32:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/6/2021 4:41:05 PM
United Therapeutics EPS in-line, beats on revenue Seeking Alpha - 5/5/2021 6:01:28 AM
United Therapeutics Corporation Reports First Quarter 2021 Financial Results PR Newswire (US) - 5/5/2021 6:00:00 AM
United Therapeutics Q1 2021 Earnings Preview Seeking Alpha - 5/4/2021 1:00:01 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2021 4:31:17 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2021 6:47:34 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2021 6:23:28 AM
United Therapeutics Corporation To Report First Quarter 2021 Financial Results Before The Market Opens On Wednesday, May 5, 2... PR Newswire (US) - 4/26/2021 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2021 4:32:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/19/2021 6:04:37 AM
United Therapeutics Announces Submission of Tyvaso DPI™ New Drug Application to FDA PR Newswire (US) - 4/19/2021 6:00:00 AM
Mannkind and United Therapeutics Reach a Milestone in the Development of Tyvaso DPI™ With New Drug Application Submitted to... GlobeNewswire Inc. - 4/19/2021 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2021 4:34:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/15/2021 4:34:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2021 9:35:55 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/2/2021 9:34:27 AM
mlkrborn   Wednesday, 10/24/12 06:33:45 PM
Re: None
Post # of 26 
New drug application for high blood pressure rejected $43 now.
Roche Hit By European Infringement Charge, XOMA Offers Shares: Healthcare Business Recap
By Mark Lawson | More Articles
October 24, 2012
The European Medicines Agency on Wednesday affirmed that it is bringing an infringement procedure against Roche (RHHBY.OB), claiming that the company did not properly check out some 80,000 reports of issues received from U.S. patients and doctors relating to 19 of the firm’s drugs, including the top performers Herceptin and Avastin. Roche could be penalized by as much as 5 percent of its yearly revenues if found guilty.
Shares of United Therapeutics Corporation (NASDAQ:UTHR) go over the cliff on word that on Wednesday the FDA rejected the firm’s new drug application for treprostinil, which is an oral treatment for high blood pressure. The agency said that it is uncertain as to whether another evaluation would help reverse its decision, but did indicate that if the company elects to conduct a further trial, it should consider a fixed dose design and more frequent dosing.
Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.
The drug maker XOMA (NASDAQ:XOMA) will to offer 13.33 million shares of common stock at $3 per share, and intends to use the proceeds for ongoing development and testing of its diabetes treatments gevokizumab and XMet platform, along with other corporate purposes.
Discovery Laboratories (NASDAQ:DSCO) shares sharply dip but rebound on the news that the commercial intro of its Surfaxin liquid medication to treat Infant Respiratory Distress Syndrome will probably be postponed until the second quarter of next year. The launch had previously been planned to occur by the end of the current year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences